Die Bedeutung der Thrombozyten bei der Entstehung und Persistenz der Glomerulonephritis

• Literatur

• 1 Zamonbi L. Anatomy and embryology of the kidney, ureter, bladder and urethra. In: Massry S.G, Glassock R.J. (Eds.) Textbook of Nephrology. Williams & Wilkins; Baltimore: 1982: 1.3-1.27.
• 2 Nackman R.L, Weksler B.B. The platelet as in inflammatory cell. In: Weissman G. (Ed.) Cell Biology and Inflammation. Elsevier; Amsterdam: 1980: 145-162.
• 3 Zimmerman T.S, Fierer J, RoArbergen H. Blood coagulation and the inflammatory response. Semin. Hematol. 14: 391-408 1977;
• 4 Holmsen H, Salganicoff L, Fukomi H. Platelet behaviour and biochemistry. In: Ogston D, Bennett B. (Eds.) Haemostasis, Physiology and Pathology. Wiley; New York: 1973: 241-319.
• 5 Heldin C-H, Westermark B, Wasteson A. Platelet-derived growth factor. Isolation by a large-scale procedure and analysis of subunit composition. Biochem. J. 193: 907-913 1981;
• 6 Nakashima Y, Hirose S, Hamashima Y. Proliferation of cultured rabbit renal glomerular cells stimulated by platelet factor. Acta Pathol. Jpn. 30: 1-7 1980;
• 7 Deuel T.F, Senior R.M, Chang D, Griffin G.L, Henrikson R.L, Kaiser E.T. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc. Natl. Acad. Sci. U.S.A. 78: 4584-4587 1981;
• 8 Deuel T.F, Senior R.M, Huang J.S. Chemotaxis of monocytes and neutrophils to platelet-derived growth factor. J. Clin. Invest. 66: 1046-1049 1982;
• 9 Dunn M.J. The role of arachidonic acid metabolites in glomerulonephritis. In: Remuzzi G, Bertani T. (Eds.) Glomerular Injury 300 Years After Morgagni. T. Wichtig; Milan: 1983
• 10 Polley M.J, Nachman R. The human complement system in thrombin-mediated platelet function. J. Exp. Med. 147: 1713-1726 1978;
• 11 Humphrey J.H, Jaques R. The release of histamine and 5-hydroxytryptamine (serotonin) from platelets by antigen-antibody reactions (in vitro). J. Physiol. 128: 9-17 1955;
• 12 Henson P.M, Spiegelberg H.L. Release of serotonin from human platelets induced by aggregated immunoglobulins of different classes and sub-classes. J. Clin. Invest. 52: 1282-1288 1973;
• 13 Clark W.E, Teraarwerk G.M, Bandali K, Lindsay R.M, Linton A.L. Platelet aggregation and release associated with immune complex formation in pig plasma. J. Lab. Clin. Med. 90: 654-665 1980;
• 14 Benveniste J, Henson P.M, Cochrane C.G. Leukocyte-dependent histamine release from rabbit platelets. J. Exp. Med. 136: 1356-1377 1972;
• 15 Benveniste J, Jouvin E, Pirotzky E, Arnoux B, Mencia-Huerta J.M, Roubin R, Vargaftig B.B. Platelet-activating factor (PAF-acether): molecular aspects of its release and pharmacological actions. Int. Arch. Allerg. Appl. Immunol. 66 (Suppl. 01) 121-126 1981;
• 16 Camussi G, Tetta C, Coda R, Benveniste J. Release of platelet-activating factor in human pathology. I. Evidence for the occurrence of basophil degranulation and release of platelet-activating factor in systemic lupus erythematosus. Lab. Invest. 44: 241-251 1981;
• 17 Camussi G, Bosio D, Sergoloni G, Tetta C, Vercellone A. Evidence for the involvement of the IgE-basophil-mastocyte system in human acute poststreptococcal glomerulonephritis. La Ricerca 8: 56-64 1978;
• 18 Martini A, Levy M, Broyer M, Hirsch J.F, Benveniste J. Sensibilisation des basophiles envers le staphylocoque au cours d’une glomerulonéphrite secondaire à l’infection d’une déviation ventriculo-atriale. J. Urol. Néphrol. 84: 349-353 1978;
• 19 George C.R.P, Slichter S.C, Qudracci L.J, Striker G.E, Harker L.A. A kinetic evaluation of hemostasis in renal disease. New Engl. J. Med. 293: 1111-1115 1974;
• 20 Clark W.F, Lewis M.L, Cameron J.S, Parsons V. Intrarenal platelet consumption in the diffuse proliferative nephritis of systemic lupus erythematosus. Clin. Sci. Mol. Med. 49: 247-252 1975;
• 21 Parbtani A, Frampton G, Cameron J.S. Measurements of platelet release substances in glomerulonephritis. A comparison of beta-thromboglobulin (BTG), platelet factor 4 (PF4) and serotonin assays. Thromb. Res. 19: 177-189 1980;
• 22 Woo K.T, Whitworth J.A, Kincaid-Smith P. Effect of antiplatelet agents on circulating platelet aggregates in patient with glomerulonephritis. Thromb. Res. 20: 663-668 1980;
• 23 Andrassy K, Ritz E, Mauerhoff T, Bommer J. What is the evidence for activated coagulation in glomerulonephritis?. Amer. J. Nephrol. 2: 293-300 1982;
• 24 Duffy J.L, Cinque T, Grishman E, Churg J. Intraglomerular fibrin platelet aggregation and subendothelial deposits in lipoid nephrosis. J. Clin. Invest. 49: 251-258 1970;
• 25 Parbtani A, Frampton G, Cameron J.S. Platelet and plasma serotonin concentrations in glomerulonephritis, II. Clin. Nephrol. 14: 112-123 1980;
• 26 Parbtani A, Frampton G, Kasai N, Yewdall V, Cameron J.S. Platelet and plasma serotonin concentrations in glomerulonephritis. III. The nephritis of systemic lupus erythematosus. Clin. Nephrol. 14: 164-172 1980;
• 27 Tomura S, Ida T, Kuriyama R, Chida Y, Takeuchi J, Motomiya T, Yamazaki H. Activation of platelets in patients with chronic proliferative glomerulonephritis and the nephrotic syndrome. Clin. Nephrol. 17: 24-30 1982;
• 28 Richman A.V, Kashic G. Endothelial and platelet reactions in the idiopathic nephrotic syndrome. Hum.. Pathol. 13: 548-553 1982;
• 29 Miller K, Dresner I.G, Michael A.F. Localization of platelet antigens in human kidney disease. Kidney Int. 18: 472-479 1980;
• 30 Duffus P, Parbtani A, Frampton G, Cameron J.S. Intraglomerular localisation of platelet-related antigens, platelet factor 4 and β-thromboglobulin in glomerulonephritis. Clin. Nephrol. 18: 298-302 1982;
• 31 Kasai N, Parbtani A, Yewdall V, Shepherd P, Verroust P, Cameron J.S. Platelet-aggregating immune complexes in glomerulonephritis. Clin. Exp. Immunol. 43: 64-72 1981;
• 32 Lavelle K.J, Noseman A.M. The influence of selective thrombocytopenia on immune complex glomerulonephritis. J. Lab. Clin. Med. 192: 737-749 1978;
• 33 Lavelle K.J, Ransdell B.A, Kleit S.A. The influence of selective thrombocytopenia on nephrotoxic nephritis. J. Lab. Clin. Med. 87: 967-975 1976;
• 34 Sindrey M, Marshall T.L, Naish P. Quantitative assessment of the effects of platelet depletion in the autologous phase of nephrotoxic serum nephritis. Clin. Exp. Immunol. 36: 90-96 1979;
• 35 Cochrane C.G. Mechanisms involved in the deposition of immune complexes in tissues. J. exp. med. 134: 75s-89s 1971;
• 36 Kniker W.T. Modulation of the inflammatory response in vivo prevention of amelioration of immune complex disease. In: Lepow I.H, Ward P.A. (Eds.) Inflammation mechanisms and Control. Academic Press; New York: 1972: 335-367.
• 37 Bolton W.K, Spargo B.A, Lewis E.J. Chronic autologous immune complex glomerulopathy: effect of Cyproheptadine. J. Lab. Clin. Med. 83: 695-704 1974;
• 38 Ida T, Tomura S, Sakurai S, Chida Y, Takeuchi J. The role of platelets in BSA nephritis. Abstract No. EX 013. Abstr. 9th Congr. Int. Soc. Nephrol. Athens. 214 1981
• 39 Nagase M, Honda N. Possible mechanisms of antiproteinuric effect of dipyridamole in nephrotic rats induced by aminonu-cleoside. 8th Int. Congr. Pharmacol., Tokyo, (Abstr.) 1981
• 40 Tojo S, Narita M, Koyama A, Sano M, Suzuki H, Tsuchiya T, Tsuchida H, Yamamoto S, Shishido H. Dipyridamole therapy in the nephrotic syndrome. Contrib. Nephrol. 9: 111-127 1978;
• 41 Cameron J.S. The treatment of severe glomerulonephritis with combined immunosuppression and anticoagulation. Proc. Sixth Int. Congr. Nephrol., Montreal. Karger, Basel 1981, pp. 419-424.
• 42 Futrakul P, Poshyachinda M, Mitra-kul C. Focal sclerosing glomerulonephritis: a kinetic evaluation of hemostasis and the effect of anticoagulant therapy: a controlled study. Clin. Nephrol. 10: 180-186 1978;
• 43 Donadio J.V, Anderson C.F, Mitchell J.C, Holley K.E, Ilstrup D.M, Fuster V. Membranoproliferative glomerulonephritis (MPGN): a prospective clinical trial of platelet inhibitor therapy. Am. Soc. Nephrol. (Abstr.), Kidney Int. 23: 28A 1982;
• 44 Hugues S. Accolement des plaquettes aux structures conjonctives perivasculaires. Thromb. Diath. Haemorrh. 8: 241-245 1962;
• 45 Barnec M, Bailey A, Gordon J, Mclntyre D. Platelet aggregation to basement membrane-associated collagens. Thromb. Res. 18: 375-388 1980;
• 46 Vargaftig B.B, Chignard M, Benveniste J. Present concepts on the mechanisms of platelet aggregation. Biochem. Pharmacol. 30: 263-271 1981;
• 47 Bertele V, Cerletti C, Schiepatti A, di Minno G, deGaetano G. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet I: 1057-1058 1981;